Divergent trends of anti-JCPyV serum reactivity and neutralizing activity in multiple sclerosis (MS) patients during treatment with natalizumab

Roberta Antonia Diotti, Ruggero Capra, Lucia Moiola, Valeria Caputo, Nicola De Rossi, Francesca Sangalli, Vittorio Martinelli, Roberto Burioni, Massimo Clementi, Nicasio Mancini

Research output: Contribution to journalArticle

Abstract

The association between natalizumab and progressive multifocal leukoencephalopathy (PML) is established, but a reliable clinical risk stratification flow-chart is lacking. New risk factors are needed, such as the possible role of the anti-JC polyomavirus (JCPyV) neutralizing antibody. In this pilot study, we analyzed this parameter during natalizumab treatment. Sequential sera of 38 multiple sclerosis patients during their first year of natalizumab treatment were collected, and grouped according to the number of infusions. For 11 patients, samples were also available after 24 infusions (T24), when progressive multifocal leukoencephalopathy (PML) risk is higher. The reactivity against VP1, the main JCPyV surface protein, and the anti-JCPyV neutralizing activity were evaluated. During the first year, a lack of correlation between anti-JCPyV antibody response and its neutralizing activity was observed: a significant decrease in anti-JCPyV antibody response was observed (p = 0.0039), not paralleled by a similar trend in the total anti-JCPyV neutralizing activity (p = 0.2239). This lack of correlation was even more evident at T24 when, notwithstanding a significant increase in the anti-JCPyV response (p = 0.0097), a further decrease of the neutralizing activity was observed (p = 0.0062). This is the first study evidencing, prospectively, the lack of correlation between the anti-JCPyV antibody response and its neutralizing activity during natalizumab treatment.

Original languageEnglish
Article number128
JournalViruses
Volume8
Issue number5
DOIs
Publication statusPublished - May 7 2016

    Fingerprint

Keywords

  • Humoral response
  • Multiple sclerosis
  • Natalizumab
  • Progressive multifocal leukoencephalopathy

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this